Cargando…

Value of tube combined with real-time ultrasound-guided accurate interstitial high-dose-rate brachytherapy for post-operative pelvic side-wall recurrences of cervical cancer

PURPOSE: Treatment of post-operative pelvic side-wall relapses of cervical cancer has always been a therapeutic challenge for radiation oncologists. Radiation dose boost to recurrent tumor by brachytherapy is necessary, but difficult to achieve. Our treatment center has successfully achieved precise...

Descripción completa

Detalles Bibliográficos
Autores principales: Mamady, Keita, Chen, Xi, Malick, Bah, Fang, Zhaohui, Niu, Huixian, Bangaly, Traoré, Liu, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8782074/
https://www.ncbi.nlm.nih.gov/pubmed/35079249
http://dx.doi.org/10.5114/jcb.2021.112114
_version_ 1784638236284420096
author Mamady, Keita
Chen, Xi
Malick, Bah
Fang, Zhaohui
Niu, Huixian
Bangaly, Traoré
Liu, Hong
author_facet Mamady, Keita
Chen, Xi
Malick, Bah
Fang, Zhaohui
Niu, Huixian
Bangaly, Traoré
Liu, Hong
author_sort Mamady, Keita
collection PubMed
description PURPOSE: Treatment of post-operative pelvic side-wall relapses of cervical cancer has always been a therapeutic challenge for radiation oncologists. Radiation dose boost to recurrent tumor by brachytherapy is necessary, but difficult to achieve. Our treatment center has successfully achieved precise transvaginal insertion of a pelvic side-wall mass, using a metal tube with real-time ultrasound guidance. This study investigates the efficacy and safety of image-guided high-dose-rate (HDR) interstitial brachytherapy (IBT) for patients with post-operative pelvic side-wall relapses. MATERIAL AND METHODS: Between 2018 and 2020, 36 post-operative pelvic side-wall relapses of cervical cancer patients receiving external beam radiotherapy (EBRT) combined with HDR-IBT were analyzed retrospectively. Doses per fraction ranged from 6.0 to 7.0 Gy, whereas cumulative equivalent doses in 2 Gy fractions ranged from 80 to 100 Gy. Effects of prognostic factors on local control (LC) and progression-free survival (PFS) were analyzed, and late toxicity data were evaluated. RESULTS: A total of thirty-six patients were included, with a median follow-up of 19.3 months. The tumor response was obtained for all patients, with radiological complete remission in 20 (55.6%) patients. Two-years LC and PFS rates were 72.2% and 47.2%, respectively. Grade II rectal toxicity was observed in 5 patients (13.9%). Multivariate analyses for LC and PFS using proportional regression model were performed, in which shape of exophytic tumor was associated with a significantly better prognosis for both LC and PFS (HR = 0.071, 0.128, p = 0.005, 0.002). Clinical target volume (CTV) D(90) remained associated with a significantly better prognosis for PFS (HR = 0.056, p = 0.000). CONCLUSIONS: A metal tube placed in the vagina, under the guidance of real-time ultrasound in transvaginal IBT for pelvis masses can be accurately achieved. The shape of exophytic tumor and CTV D(90) were associated with a significantly better prognosis for PFS, and the shape of exophytic tumor was also associated with a better prognosis for LC. Therefore, radiation dose boost using IBT can improve the prognosis of patients with post-operative pelvic side-wall recurrences of cervical cancer.
format Online
Article
Text
id pubmed-8782074
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-87820742022-01-24 Value of tube combined with real-time ultrasound-guided accurate interstitial high-dose-rate brachytherapy for post-operative pelvic side-wall recurrences of cervical cancer Mamady, Keita Chen, Xi Malick, Bah Fang, Zhaohui Niu, Huixian Bangaly, Traoré Liu, Hong J Contemp Brachytherapy Original Paper PURPOSE: Treatment of post-operative pelvic side-wall relapses of cervical cancer has always been a therapeutic challenge for radiation oncologists. Radiation dose boost to recurrent tumor by brachytherapy is necessary, but difficult to achieve. Our treatment center has successfully achieved precise transvaginal insertion of a pelvic side-wall mass, using a metal tube with real-time ultrasound guidance. This study investigates the efficacy and safety of image-guided high-dose-rate (HDR) interstitial brachytherapy (IBT) for patients with post-operative pelvic side-wall relapses. MATERIAL AND METHODS: Between 2018 and 2020, 36 post-operative pelvic side-wall relapses of cervical cancer patients receiving external beam radiotherapy (EBRT) combined with HDR-IBT were analyzed retrospectively. Doses per fraction ranged from 6.0 to 7.0 Gy, whereas cumulative equivalent doses in 2 Gy fractions ranged from 80 to 100 Gy. Effects of prognostic factors on local control (LC) and progression-free survival (PFS) were analyzed, and late toxicity data were evaluated. RESULTS: A total of thirty-six patients were included, with a median follow-up of 19.3 months. The tumor response was obtained for all patients, with radiological complete remission in 20 (55.6%) patients. Two-years LC and PFS rates were 72.2% and 47.2%, respectively. Grade II rectal toxicity was observed in 5 patients (13.9%). Multivariate analyses for LC and PFS using proportional regression model were performed, in which shape of exophytic tumor was associated with a significantly better prognosis for both LC and PFS (HR = 0.071, 0.128, p = 0.005, 0.002). Clinical target volume (CTV) D(90) remained associated with a significantly better prognosis for PFS (HR = 0.056, p = 0.000). CONCLUSIONS: A metal tube placed in the vagina, under the guidance of real-time ultrasound in transvaginal IBT for pelvis masses can be accurately achieved. The shape of exophytic tumor and CTV D(90) were associated with a significantly better prognosis for PFS, and the shape of exophytic tumor was also associated with a better prognosis for LC. Therefore, radiation dose boost using IBT can improve the prognosis of patients with post-operative pelvic side-wall recurrences of cervical cancer. Termedia Publishing House 2021-12-30 2021-12 /pmc/articles/PMC8782074/ /pubmed/35079249 http://dx.doi.org/10.5114/jcb.2021.112114 Text en Copyright © 2021 Termedia https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/) )
spellingShingle Original Paper
Mamady, Keita
Chen, Xi
Malick, Bah
Fang, Zhaohui
Niu, Huixian
Bangaly, Traoré
Liu, Hong
Value of tube combined with real-time ultrasound-guided accurate interstitial high-dose-rate brachytherapy for post-operative pelvic side-wall recurrences of cervical cancer
title Value of tube combined with real-time ultrasound-guided accurate interstitial high-dose-rate brachytherapy for post-operative pelvic side-wall recurrences of cervical cancer
title_full Value of tube combined with real-time ultrasound-guided accurate interstitial high-dose-rate brachytherapy for post-operative pelvic side-wall recurrences of cervical cancer
title_fullStr Value of tube combined with real-time ultrasound-guided accurate interstitial high-dose-rate brachytherapy for post-operative pelvic side-wall recurrences of cervical cancer
title_full_unstemmed Value of tube combined with real-time ultrasound-guided accurate interstitial high-dose-rate brachytherapy for post-operative pelvic side-wall recurrences of cervical cancer
title_short Value of tube combined with real-time ultrasound-guided accurate interstitial high-dose-rate brachytherapy for post-operative pelvic side-wall recurrences of cervical cancer
title_sort value of tube combined with real-time ultrasound-guided accurate interstitial high-dose-rate brachytherapy for post-operative pelvic side-wall recurrences of cervical cancer
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8782074/
https://www.ncbi.nlm.nih.gov/pubmed/35079249
http://dx.doi.org/10.5114/jcb.2021.112114
work_keys_str_mv AT mamadykeita valueoftubecombinedwithrealtimeultrasoundguidedaccurateinterstitialhighdoseratebrachytherapyforpostoperativepelvicsidewallrecurrencesofcervicalcancer
AT chenxi valueoftubecombinedwithrealtimeultrasoundguidedaccurateinterstitialhighdoseratebrachytherapyforpostoperativepelvicsidewallrecurrencesofcervicalcancer
AT malickbah valueoftubecombinedwithrealtimeultrasoundguidedaccurateinterstitialhighdoseratebrachytherapyforpostoperativepelvicsidewallrecurrencesofcervicalcancer
AT fangzhaohui valueoftubecombinedwithrealtimeultrasoundguidedaccurateinterstitialhighdoseratebrachytherapyforpostoperativepelvicsidewallrecurrencesofcervicalcancer
AT niuhuixian valueoftubecombinedwithrealtimeultrasoundguidedaccurateinterstitialhighdoseratebrachytherapyforpostoperativepelvicsidewallrecurrencesofcervicalcancer
AT bangalytraore valueoftubecombinedwithrealtimeultrasoundguidedaccurateinterstitialhighdoseratebrachytherapyforpostoperativepelvicsidewallrecurrencesofcervicalcancer
AT liuhong valueoftubecombinedwithrealtimeultrasoundguidedaccurateinterstitialhighdoseratebrachytherapyforpostoperativepelvicsidewallrecurrencesofcervicalcancer